598 related articles for article (PubMed ID: 30442814)
1. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.
Hsu JM; Li CW; Lai YJ; Hung MC
Cancer Res; 2018 Nov; 78(22):6349-6353. PubMed ID: 30442814
[TBL] [Abstract][Full Text] [Related]
2. Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy.
Lee TA; Tsai EY; Liu SH; Hsu Hung SD; Chang SJ; Chao CH; Lai YJ; Yamaguchi H; Li CW
Cancer Res; 2024 Mar; 84(6):800-807. PubMed ID: 38231470
[TBL] [Abstract][Full Text] [Related]
3. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
Li CW; Lim SO; Xia W; Lee HH; Chan LC; Kuo CW; Khoo KH; Chang SS; Cha JH; Kim T; Hsu JL; Wu Y; Hsu JM; Yamaguchi H; Ding Q; Wang Y; Yao J; Lee CC; Wu HJ; Sahin AA; Allison JP; Yu D; Hortobagyi GN; Hung MC
Nat Commun; 2016 Aug; 7():12632. PubMed ID: 27572267
[TBL] [Abstract][Full Text] [Related]
4. Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton.
Horita H; Law A; Hong S; Middleton K
Neoplasia; 2017 Apr; 19(4):346-353. PubMed ID: 28319808
[TBL] [Abstract][Full Text] [Related]
5. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
[TBL] [Abstract][Full Text] [Related]
6. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Wu Y; Zhang C; Liu X; He Z; Shan B; Zeng Q; Zhao Q; Zhu H; Liao H; Cen X; Xu X; Zhang M; Hou T; Wang Z; Yan H; Yang S; Sun Y; Chen Y; Wu R; Xie T; Chen W; Najafov A; Ying S; Xia H
Nat Commun; 2021 Apr; 12(1):2346. PubMed ID: 33879767
[TBL] [Abstract][Full Text] [Related]
7. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
8. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Cha JH; Yang WH; Xia W; Wei Y; Chan LC; Lim SO; Li CW; Kim T; Chang SS; Lee HH; Hsu JL; Wang HL; Kuo CW; Chang WC; Hadad S; Purdie CA; McCoy AM; Cai S; Tu Y; Litton JK; Mittendorf EA; Moulder SL; Symmans WF; Thompson AM; Piwnica-Worms H; Chen CH; Khoo KH; Hung MC
Mol Cell; 2018 Aug; 71(4):606-620.e7. PubMed ID: 30118680
[TBL] [Abstract][Full Text] [Related]
9. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.
Feng C; Zhang L; Chang X; Qin D; Zhang T
Front Immunol; 2023; 14():1230135. PubMed ID: 37554324
[TBL] [Abstract][Full Text] [Related]
10. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
[TBL] [Abstract][Full Text] [Related]
11. Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave.
Yu X; Li W; Young KH; Li Y
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829931
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy.
Chai F; Li P; Liu X; Zhou Z; Ren H
J Mol Cell Biol; 2024 Apr; 15(11):. PubMed ID: 37993416
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour potential of PD-L1/PD-1 post-translational modifications.
Zhou S; Zhu J; Xu J; Gu B; Zhao Q; Luo C; Gao Z; Chin YE; Cheng X
Immunology; 2022 Dec; 167(4):471-481. PubMed ID: 36065492
[TBL] [Abstract][Full Text] [Related]
14. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Zhang X; Huang X; Xu J; Li E; Lao M; Tang T; Zhang G; Guo C; Zhang X; Chen W; Yadav DK; Bai X; Liang T
Nat Commun; 2021 Jul; 12(1):4536. PubMed ID: 34315872
[TBL] [Abstract][Full Text] [Related]
15. LIN28/
Chen Y; Xie C; Zheng X; Nie X; Wang Z; Liu H; Zhao Y
Cancer Immunol Res; 2019 Mar; 7(3):487-497. PubMed ID: 30651289
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
Verdura S; Cuyàs E; Cortada E; Brunet J; Lopez-Bonet E; Martin-Castillo B; Bosch-Barrera J; Encinar JA; Menendez JA
Aging (Albany NY); 2020 Jan; 12(1):8-34. PubMed ID: 31901900
[TBL] [Abstract][Full Text] [Related]
17. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation.
Shi C; Wang Y; Wu M; Chen Y; Liu F; Shen Z; Wang Y; Xie S; Shen Y; Sang L; Zhang Z; Gao Z; Yang L; Qu L; Yang Z; He X; Guo Y; Pan C; Che J; Ju H; Liu J; Cai Z; Yan Q; Yu L; Wang L; Dong X; Xu P; Shao J; Liu Y; Li X; Wang W; Zhou R; Zhou T; Lin A
Nat Commun; 2022 Nov; 13(1):6951. PubMed ID: 36376293
[TBL] [Abstract][Full Text] [Related]
18. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
19. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
[TBL] [Abstract][Full Text] [Related]
20. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
